# Reza Halse

> Reza Halse is a Series A investor at RA Capital Management backing Biotechnology. See 8 investments, check sizes, portfolio and contact details. Updated Aug…

- Type: Angel Investor
- Fund: [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management)
- Location: London, United Kingdom
- Total investments: 8
- Last investment: Apr 2023
- Lead investor: 13%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/reza-halse-638aba4

Reza Halse is a Series A investor at RA Capital Management in London focused on Biotechnology and Health Care. Reza Halse - Partner, RA Ventures @ RA Capital Management

## Contacts

5 contacts available for Reza Halse: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/reza-halse?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 63% |
| Health Care | 4 | 50% |
| Therapeutics | 4 | 50% |
| Medical Device | 1 | 13% |
| Information Technology | 1 | 13% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 50% |
| Seed | 2 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 4 | 50% |
| Denmark | 1 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| ADCendo | ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment. | $34M | Series A | Apr 04, 2023 |  |
| ADCendo | ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment. | $61.8M | Series A | Apr 29, 2021 |  |
| Caraway Therapeutics | Rheostat’s mission is to invent novel treatments for neurodegenerative disease through modulation of mitophagy and autophagy. They believe that the degradation of toxic cellular components, whether they are damaged organelles or aggregated proteins, is a fundamental node of biology. Mutations that impair these clearance pathways cause multipleneurodegenerative diseases, many of which are associated with cognitive impairment. They aim to leverage our understanding of these critical pathways to discover and develop novel small molecules that will restore cellular balance and treat neurodegenerative and rare diseases. | $23M | Series A | Nov 26, 2018 |  |
| Spero Therapeutics | Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development, and a focus on high potential, novel mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterialinfections. Its lead program addresses a novel target driving virulence and persistence of pseudomonas aeruginosa infections and other gram-negative pathogens. | $30M | Series A | Jun 08, 2015 |  |
| Raze Therapeutics | Raze Therapeutics is leading the discovery and development of a new class of oncology therapeutics that target key metabolic pathways. Raze is advancing a pipeline of therapeutics based on new biological insights into how cancer cells reprogram metabolism to activate central anabolic processes essential for tumors to grow and survive. | $24M | Series A | Oct 14, 2014 |  |
| Lysosomal Therapeutics | Lysosomal Therapeutics is dedicated to innovative small-molecule research and development in the field of neurodegeneration, yielding new treatment options for patients with severe neurological diseases. Their strategy leverages the clinically-validated link between lysosome-based genetic disorders and neurodegenerative diseases to establish aunique and effective molecular platform for novel drug discovery. LTI’s lead program targets Gaucher-related neurodegeneration, Parkinson’s disease, and other synucleinopathies. | $4.8M | Seed | May 12, 2014 |  |
| Spero Therapeutics | Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development, and a focus on high potential, novel mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterialinfections. Its lead program addresses a novel target driving virulence and persistence of pseudomonas aeruginosa infections and other gram-negative pathogens. | $3M | Series A | Apr 09, 2014 |  |
| Spero Therapeutics | Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development, and a focus on high potential, novel mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterialinfections. Its lead program addresses a novel target driving virulence and persistence of pseudomonas aeruginosa infections and other gram-negative pathogens. |  | Seed | Dec 31, 2013 |  |

8 of 8 investments shown.

## Co-investors
- [Atlas Venture](https://shizune.co/investors/profile/atlas-venture) — VC Fund, 4 deals together
- [Gilde Healthcare](https://shizune.co/investors/profile/gilde-healthcare-partners) — VC Fund, 2 deals together
- [HealthCap](https://shizune.co/investors/profile/healthcap) — VC Fund, 2 deals together
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 2 deals together
- [SR One](https://shizune.co/investors/profile/sr-one) — VC Fund, 2 deals together
- [Ysios Capital](https://shizune.co/investors/profile/ysios-capital) — VC Fund, 2 deals together

## About RA Capital Management

VC Fund · Boston, United States

RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.

5 contacts available at RA Capital Management.

| Name | Title | Profile |
| --- | --- | --- |
| Cristina Ghenoiu | Principal | https://shizune.co/investors/profile/cristina-ghenoiu |
| Ajay Yekkirala | VP, Head of Biology | https://shizune.co/investors/profile/ajay-yekkirala-9184 |
| Andrew Levin | Managing Director | https://shizune.co/investors/profile/andrew-levin |
| Barbara Herbst | Deputy Chief Compliance Officer | https://shizune.co/investors/profile/barbara-herbst |
| Dan Marks | Venture Senior Associate | https://shizune.co/investors/profile/dan-marks |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Reza Halse invest in?

Reza Halse invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Seed stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Reza Halse?

Public channels for Reza Halse include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Reza Halse last invest?

The most recent investment recorded for Reza Halse closed in Apr 2023. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co